7 results about "Gene vector" patented technology

This invention relates to the field of genetic engineering, specifically to an HSL mutant, gene, vector, cell, composition, and its applications. The mutant is selected from... Os HSL4 enzyme, Sb HSL1 enzyme, Zm HSL1A enzyme, Hv HSL6D enzyme and Zm A mutant of at least one of the HSL1B enzymes. The HSL mutants, genes, vectors, cells, and compositions provided by this invention can improve plant resistance to HPPD inhibitors.

This invention relates to the field of gene vector technology, and more particularly to an ionizable comb-like polymer, its preparation method, and its applications. This comb-like polymer is a block polymer, comprising at least one block unit. Each block unit includes a first block, a second block, and a third block linked by covalent bonds. It exhibits high molecular flexibility and readily binds to nucleic acid-like substances to form polymer / nucleic acid complexes. Due to the presence of easily degradable intracellular glycosidic bonds in its structure, the polymer demonstrates high transfection efficiency. Furthermore, cell experiments show that the polymer / nucleic acid complex exhibits low toxicity to cells and significantly improves cell survival compared to the positive control. Therefore, it holds promise for widespread application in cell transfection. The preparation method provided by this invention utilizes a redox amination tandem reaction to directly prepare the target product, eliminating the need for intermediate product purification processes. This simple process facilitates large-scale production.

This invention belongs to the field of biodetection technology, specifically relating to a material for detecting anti-NF155 antibodies and its preparation method. This invention constructs an expression plasmid capable of highly expressing the NF155 antigen, transfects it into HEK293T cells, and modifies the pCDH vector with enhancers during construction. Subsequently, a modified cell culture protocol is used to obtain a material for detecting anti-NF155 antibodies based on a cell immunofluorescence methodology. This invention uses a cell immunofluorescence methodology to maximize the preservation of the antigen's spatial conformation through cell expression and antigen immobilization, preventing false negatives due to changes in binding sites. This invention selects the lentiviral vector pCDH to avoid the problem of non-specific binding that is difficult to distinguish, as the proteins expressed by common target gene vectors such as pcDNA3.1 may themselves contain antibody binding sites. This improves detection specificity and solves the problem of false negatives.

This invention relates to effective and safe compositions comprising anionic gold-polydopamine core-shell nanoworms as alternative gene vectors to overcome endosome escape bottlenecks. The nanoworms can be used in methods for delivering therapeutic oligonucleotides to subjects. A polydopamine shell supports surface-adsorbed nucleic acids. Nanoworms encapsulating anionic nucleic acids can then enter cells without transfection agents and activate ClC3H in late endosomes. + / Cl ‑ Ion exchangers, to mediate H + and Cl ‑ Nanoworms accumulate within vesicles, leading to membrane rupture and ultimately escaping into the cytosol without cell-penetrating peptides or mechanical stimulation. Nanoworms can also be used for cell programming (i.e., primary macrophage polarization and stem cell differentiation) and for treating diseases (such as renal fibrosis and acute liver injury).

The application discloses a method for transgene and / or gene editing of Brassica crops mediated by co-transformation strategy, and belongs to the technical field of genetic engineering.The method comprises the following steps: transforming a development regulator vector and a target gene vector into Agrobacterium rhizogenes K599 respectively to prepare a mixed bacteria solution of double strains; infecting a Brassica vegetable explant; inducing adventitious buds after co-culturing; and screening different types of transgenic buds through fluorescence labeling, phenotype observation and molecular identification.The method is simple and efficient, and can effectively avoid adverse phenotypes such as transgenic plant deformity caused by continuous overexpression of the development regulator, and can obtain a gene editing homozygous mutant in the T0 generation, so that the method has a wide application prospect in the research of Brassica crop functional genomics, gene editing and crop genetic improvement.

The present invention provides gene therapy plasmids and transgenes comprising soluble tissue non-specific alkaline phosphatase, recombinant virus vectors for delivery of said viral plasmids and transgenes and medical uses relating to the treatment of pyrophosphate deposition diseases and / or hypophosphatasia.

Described herein are compositions and techniques related to generation and therapeutic application of engineered extracellular vesicles. Engineered extracellular vesicles are vesicles (i.e., exosomes) comprising at least one engineered fusion polypeptide further comprising a vesicle targeting domain, scaffold linker domain, and signaling domain (i.e., a multi-effector signaling domain) wherein the signaling domain targets and interacts with a biological target, such as cell surface receptors. Said engineered fusion proteins can be organized in genetic vector constructs, expressed in mammalian cells, wherein the vesicle targeting domains anchor to extracellular vesicles such as exosomes, thereby presenting their joined multi-effector signaling domain which can relay a signal to target cells. Engineered extracellular vesicles adopt the hallmark biophysical and biochemical features of extracellular vesicles, allowing for rapid deployment and scale-up. Importantly, this strategy can allow for kinetically favorable signal generation and signal propagation to a target cell.